336 related articles for article (PubMed ID: 25648357)
21. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
[TBL] [Abstract][Full Text] [Related]
22. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US
Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590
[TBL] [Abstract][Full Text] [Related]
23. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
24. In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma.
Barazzuol L; Jena R; Burnet NG; Jeynes JC; Merchant MJ; Kirkby KJ; Kirkby NF
Radiat Res; 2012 May; 177(5):651-62. PubMed ID: 22468703
[TBL] [Abstract][Full Text] [Related]
25. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
26. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
27. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
28. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
29. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi ME; Stupp R
Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
[No Abstract] [Full Text] [Related]
30. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
31. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
[TBL] [Abstract][Full Text] [Related]
32. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
[TBL] [Abstract][Full Text] [Related]
33. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
34. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
35. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
Tseng JH; Chen CY; Chen PC; Hsiao SH; Fan CC; Liang YC; Chen CP
Oncotarget; 2017 Feb; 8(9):14666-14679. PubMed ID: 28108734
[TBL] [Abstract][Full Text] [Related]
36. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
37. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
38. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
Combs SE; Schulz-Ertner D; Roth W; Herold-Mende C; Debus J; Weber KJ
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):873-82. PubMed ID: 17544000
[TBL] [Abstract][Full Text] [Related]
39. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
40. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
